Wafik S. El-Deiry: Outstanding discussions at the WIN Consortium in cancer personalized medicine molecular tumor board
Wafik S. El-Deiry posted on LinkedIn:
“Outstanding discussions earlier today at the international WIN Consortium in cancer personalized medicine molecular tumor board with great suggestions to consider as options for therapy in complicated progressing tumors.
We discussed BRCA2, FBXW7, PIK3CA, BRAF amplification, EGFR amplification, TMB, potential toxicities, therapy, clinical trials, drug dosing and therapy combination prioritization.
Special thanks to our WIN MTB Chair Razelle Kurzrock at MCW Cancer Center and to Dr. Gerald Batist at McGill University for some great comments at today’s meeting.”
Source: Wafik El-Deiry/LinkedIn
Wafik El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023